Abstract
The integration of big data analytics into drug discovery has opened up new possibilities for personalized medicine, allowing treatments to be tailored to the genetic, molecular, and environmental profiles of individual patients. This article explores how big data technologies are revolutionizing the drug discovery process, from target identification and biomarker discovery to clinical trials and post-market surveillance. We examine the role of big data in personalized drug development, highlighting key computational tools and methodologies used to analyze complex biomedical datasets. Additionally, the article discusses challenges in implementing big data approaches, ethical considerations, and future directions for leveraging big data in the pursuit of personalized drug therapies.
All articles published in the American Journal of Bioinformatics (AJB) are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license, authors retain full copyright of their work and grant permission to anyone to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Conditions:
-
Attribution: Appropriate credit must be given to the original author(s) and the source, a link to the license must be provided, and any changes made must be indicated.
-
No additional restrictions: You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This open-access license ensures that scholarly work published in AJB is freely accessible and usable, promoting knowledge dissemination and academic collaboration worldw